Published on in Vol 8 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/43991, first published .
Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non–Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data

Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non–Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data

Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non–Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data

Journals

  1. Aleppo G, Hirsch I, Parkin C, McGill J, Galindo R, Kruger D, Levy C, Forlenza G, Umpierrez G, Grunberger G, Bergenstal R. Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking. Diabetes Technology & Therapeutics 2023;25(10):741 View
  2. Kim J, Jin S, Andrade S, Chen B, Kim J. Real-World Continuous Glucose Monitoring Data from a Population with Type 1 Diabetes in South Korea: Nationwide Single-System Analysis. Diabetes Technology & Therapeutics 2024;26(6):394 View
  3. Wright E, Roberts G, Chuang J, Nabutovsky Y, Virdi N, Miller E. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone. Diabetes Technology & Therapeutics 2024 View
  4. Seufert J, Dänschel I, Gölz S, Haller N, Kulzer B, Tan S, Schnell O, Wiesner T, Kroeger J. Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung. Diabetologie und Stoffwechsel 2024 View